Anti IL-18 (GSK1070806) in Behcet's Disease

Behcet's Disease Clinical Trial

Official title:

An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03522662
• Other study ID #: Behcet1070806
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 1, 2018
• Est. completion date: April 1, 2020

Study information

• Verified date: May 2018
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: Rona M Smith, MD MRCP
• Phone: 00441223217259
• Email: rona.smith[@]addenbrookes.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary outcome measure of the study is to demonstrate the safety and tolerability of GSK1070806 in the Behcet's disease population at 24 weeks, with biochemical and clinical efficacy and mechanistic studies to further explore the pathogenesis of Behcet's disease important secondary and exploratory outcomes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: April 1, 2020
• Est. primary completion date: April 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have given written informed consent to participate

• Be aged 18 years and over

• Have a diagnosis of Behcet's disease (according to the International Study Group (ISG) diagnostic guidelines or International Criteria for BD (ICBD)).

• Have active disease, severe enough to necessitate the use of biological therapy at the time of enrolment (i.e. Subjects have refractory disease as defined by the UK Centres of Excellence criteria as failure to respond to steroid and/or immunosuppressive therapy with significant or major organ-threatening disease.

Exclusion Criteria:

1. Age under 18 years

2. Allergies to humanized monoclonal antibodies

3. Subjects who have received any of the following agents within 364 days of day 0:

1. Alemtuzumab

2. Rituximab or any other B cell depleting or modulating biological agent

4. Subjects who have received any of the following agents within 180 days of day 0:

1. Cyclophosphamide

2. Anti-thymocyte globulin

5. Subjects who have received any of the following agents within 90 days of Day 0:

1. Intravenous immunoglobulin (IVIG)

2. Plasmapheresis

6. Subjects who have received any of the following agents within 30 days of Day 0:

1. Anti-TNF (e.g. adalimumab, etanercept, infliximab)

2. Anti-IL-6 therapy (e.g. tocilizumab)

3. Interleukin-1 receptor antagonist (e.g. anakinra)

4. Alpha interferon

5. Any live vaccine

7. Subjects who have received any other investigational product within 30 days, 5 half lives or twice the duration of the biological effect, whichever is longer.

8. Subjects required more than 15mg prednisolone daily in the 4 week run in phase.

9. Positive human immunodeficiency virus (HIV) antibody test

10. Positive serology for Hepatitis B (HB), defined as: (i) HB surface antigen positive (HBsAg+) OR (ii) HB core antibody positive (HBcAb+)

11. Positive Hepatitis C (HCV) antibody test

12. Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and a positive (not indeterminate) QuantiFERON®-TB Gold test.

13. Evidence of chronic infection requiring long term antimicrobial therapy

14. Serum IgG level < 3g/l

15. Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, and carcinoma in situ of the uterine cervix.

16. QTc interval (single or average) > 480msec or in subjects with bundle branch block QTc > 500msec (these criteria do not apply to subjects with predominantly paced rhythm).

17. Liver function: ALT > 2xULN and bilirubin > 1.5 ULN (isolated bilirubin > 1.5 ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)

18. Compliance: is unlikely to comply with scheduled study visits based on investigator judgment or has a history of substance abuse, psychiatric disorder or condition that may compromise communication with the investigator

19. Women who are pregnant or breast feeding

20. Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for one month before and 12 months after administration of GSK1070806

Related Conditions & MeSH terms

• Behcet Syndrome
• Behcet's Disease

Intervention

Drug:
• GSK1070806
Single 10mg/kg infusion on Day 0

Locations

Country	Name	City	State
United Kingdom	Addenbrooke's Hospital, University of Cambridge NHS Foundation Trust	Cambridge

Sponsors (1)

Lead Sponsor	Collaborator
Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Comparison of serum free IL-18 and total IL-18 levels	Pre and post GSK1070806	6 weeks
Other	Comparison of downstream Th1 cytokines	Including interferon gamma, IP-10, IL-10, IL-2, IL-1ß and TNF. Pre and post GSK1070806.	6 weeks
Primary	The occurrence of all moderate, severe and life threatening adverse events	Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)	24 weeks
Secondary	All adverse events, including mild events	Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)	24 weeks
Secondary	Measurement of disease activity	Using a clinical scoring tool, the Behcet's disease current activity form (BDCAF)	24 weeks
Secondary	Measurement of the accumulation of damage	Using a clinical scoring tool, the Vasculitis Damage Index (VDI)	24 weeks